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A Randomized Feasibility Trial of a Novel, Integrative, and
Intensive Virtual Rehabilitation Program for Service Members
Post-Acquired Brain Injury
Kiara H. Buccellato*†; Michelle Nordstrom*†‡§; Justin M. Murphy*†; Grigore C. Burdea‖;
Kevin Polistico‖; Gregory House‖; Nam Kim‖; Namrata Grampurohit‖; Jeff Sorensen*†;
Brad M. Isaacson†‡¶; US Army COL (ret) Paul F. Pasquina, ‡§
ABSTRACT
Introduction
Acquired Brain Injury, whether resulting from Traumatic brain injury (TBI) or Cerebral Vascular Accident (CVA),
represent major health concerns for the Department of Defense and the nation. TBI has been referred to as the “signature”
injury of recent U.S. military conflicts in Iraq and Afghanistan – affecting approximately 380,000 service members from
2000 to 2017; whereas CVA has been estimated to effect 795,000 individuals each year in the United States. TBI and CVA
often present with similar motor, cognitive, and emotional deficits; therefore the treatment interventions for both often
overlap. The Defense Health Agency and Veterans Health Administration would benefit from enhanced rehabilitation
solutions to treat deficits resulting from acquired brain injuries (ABI), including both TBI and CVA. The purpose of this
study was to evaluate the feasibility of implementing a novel, integrative, and intensive virtual rehabilitation system for
treating symptoms of ABI in an outpatient clinic. The secondary aim was to evaluate the system’s clinical effectiveness.
Materials and Methods
Military healthcare beneficiaries with ABI diagnoses completed a 6-week randomized feasibility study of the Bright-
Brainer Virtual Rehabilitation (BBVR) system in an outpatient military hospital clinic. Twenty-six candidates were
screened, consented and randomized, 21 of whom completed the study. The BBVR system is an experimental adjunct
ABI therapy program which utilizes virtual reality and repetitive bilateral upper extremity training. Four self-report
questionnaires measured participant and provider acceptance of the system. Seven clinical outcomes included the Fugl-
Meyer Assessment of Upper Extremity, Box and Blocks Test, Jebsen-Taylor Hand Function Test, Automated Neuropsy-
chological Assessment Metrics, Neurobehavioral Symptom Inventory, Quick Inventory of Depressive Symptomatology-
Self-Report, and Post Traumatic Stress Disorder Checklist- Civilian Version. The statistical analyses used bootstrapping,
non-parametric statistics, and multilevel/hierarchical modeling as appropriate. This research was approved by the Walter
Reed National Military Medical Center and Uniformed Services University of the Health Sciences Institutional Review
Boards.
Results
All of the participants and providers reported moderate to high levels of utility, ease of use and satisfaction with the
BBVR system (xx̄ = 73–86%). Adjunct therapy with the BBVR system trended towards statistical significance for the
measure of cognitive function (ANAM [xx̄ = −1.07, 95% CI −2.27 to 0.13, p = 0.074]); however, none of the other
effects approached significance.
Conclusion
This research provides evidence for the feasibility of implementing the BBVR system into an outpatient military setting
for treatment of ABI symptoms. It is believed these data justify conducting a larger, randomized trial of the clinical
effectiveness of the BBVR system.
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INTRODUCTION
Frequent use of improvised explosive devices (IEDs) in Oper-
ation Iraqi Freedom (OIF) and Operation Enduring Freedom
(OEF) resulted in traumatic brain injury (TBI) being called
the signature injury of recent conflicts.1 According to Depart-
ment of Defense (DoD) reports, 379,519 service members
received a TBI diagnosis from 2000 to 2017.2 Traumatic
brain injuries are a subtype of acquired brain injury (ABI),
which refers to any post-natal brain injury.3 Acquired brain
injuries commonly present with symptoms of cognitive and
motor impairment, and emotional instability that may persist
for years and affect performance of activities of daily living
(ADLs).4,5 Though survival rates of mild TBI (mTBI) are
high, the resulting diminished quality of life calls for a greater
focus on long-term TBI rehabilitative care.6
Another category of ABI, Cerebral Vascular Accident
(CVA), often presents with similar impairments, such as
diminished memory, upper extremity weakness and spasms,
and depression.7–9 Moreover, those who have experienced
a TBI are also at higher risk of CVA than those who have
not.10,11 The majority of neurological recovery after TBI and
CVA typically occurs within the first 6 months of injury,
but training factors such as intensity, repetition, duration,
patient motivation, and patient engagement may impact long-
term treatment effectiveness on individuals in the chronic
phase.12–16
Traditional rehabilitation protocols for individual’s post-
ABI, such as proprioceptive neuromuscular facilitation (PNF),
are widely recognized but underutilized by therapists.17
Additionally, hands-on interventions, while well known, have
limited evidence supporting their success with chronic ABI
rehabilitation.18 With technological advancements it may be
possible to link the traditional therapies with progressive
opportunities, while also increasing patient engagement and
decreasing provider burden.
One method of post-ABI rehabilitation with growing clini-
cal acceptance is virtual reality (VR). Virtual reality is defined
as a synthetic world that responds in real time to changes
in user input, creating a constantly-engaging environment in
which users participate.19 Virtual rehabilitation utilizes VR
in a variety of clinically relevant domains,20 and offers a
unique platform for ABI rehabilitation by engaging patients
in appropriately challenging tasks.21 It provides the needed
intensity of care, can unify treatment in an integrative rehabil-
itation, and can involve bimanual interactions engaging both
hemispheres.22 A review of studies evaluating improvements
in cognitive domains (e.g., executive function) indicates that
computer-based cognitive rehabilitation programs which are
tailored to the participant’s abilities often produce greater
results compared to non-personalized cognitive rehabilitation
computer programs.23
BrightBrainer Virtual Rehabilitation System
The BrightBrainer Virtual Rehabilitation (BBVR) program
is a computer-based VR platform that utilizes real-time
bimanual interaction for the purpose of increasing cognitive
engagement compared to simple mouse, or single finger touch
interaction. Bilateral training has been found to promote
improved motor functioning for people who have experienced
ABI, above and beyond unilateral training.24,25 This system
facilitates split attention training (focusing), task sequencing
(alternating actions between arms), hand-eye coordination,
and dual tasking through use of simultaneous cognitive and
motor challenges. Though the BBVR system was originally
developed for geriatric patients with CVA, the use of adaptable
games, bimanual tasks, and repetition may make it translatable
as a tool for ABI treatment in a military population.26
While literature on VR therapy post-ABI is abundant, many
of the systems either focus only on rehabilitation of one aspect
of post-ABI deficits,27 or are too physically large to implement
in most clinics.28 The BBVR system is unique because it com-
bines cognitive and physical training in a compact, adaptive
VR system which can be implemented largely unobtrusively
into clinical space. This pilot study implemented the BBVR
system within a Military Treatment Facility’s (MTF) outpa-
tient occupational therapy clinic as a 6-week intervention for
participants with ABI. The primary aim was to evaluate the
feasibility of integrating the BBVR system into the clinic for
both 1-on-1 provider-participant interaction and concurrent
treatment in which 1 provider oversees 2 participants at a time.
The 3 secondary aims were: (1) to evaluate the preliminary
clinical effectiveness of the BBVR system in terms of motor
function, cognitive performance, and behavioral/emotional
symptoms; (2) to evaluate the dose-response effect of the
BBVR system; and (3) to evaluate the correlation between
participant-level BBVR game performance and longitudinal
change in clinical outcomes.
METHODS
Subjects
Potential candidates were identified through clinician referral.
Eligible participants were defined as adult (≥18 years of age)
military healthcare beneficiaries ABI endorsing symptoms
of cognitive, emotional, or physical dysfunction. Presence
of ABI diagnosis was confirmed through the participant’s
electronic health records upon consent. Exclusion criteria
were: (i) inability to comprehend written consent documents,
(ii) visual impairment that might prevent system use, (iii)
insufficient dexterity to operate BBVR system controllers, and
(iv) concurrent enrollment in another cognitive rehabilitation
study. This study was approved to consent up to 30 participants
and aimed to complete at least 20 (accounting for attrition),
which was determined via clinical judgement to be a suffi-
cient number for assessing feasibility. All study procedures
were completed in an outpatient occupational therapy clinic.
Institutional review board approval was granted through the
Walter Reed National Military Medical Center and Uniformed
Services University of the Health Sciences.
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Outcomes
Four self-report questionnaires measured participant and
provider acceptance of the BBVR program. (Appendices
1–4)29,30 Two of these measures were completed by the
participant, and the remaining 2 by the provider. These
questionnaires were used as the primary outcome measures
in order to assess the feasibility of using this system in an
outpatient clinic setting. Since the providers were involved
in all assessment time points, including initial and final
assessments, blinding was not possible.
Seven clinical outcomes were used to assess cognitive,
behavioral, and motor functioning. Three of these assessments
measured upper-extremity motor functioning: the Fugl-Meyer
Assessment of Upper Extremity (FMA-UE),31 Box and
Blocks Test (BBT),32 and Jebsen-Taylor Hand Function
Test (JHFT).33 Cognitive function was measured using
the Automated Neuropsychological Assessment Metrics
(ANAM).34 Three behavioral self-report questionnaires were
used: the Neurobehavioral Symptom Inventory (NSI),35 the
Quick Inventory of Depressive Symptomatology-Self-Report
(QIDS-SR),36 and the Post Traumatic Stress Disorder (PTSD)
Checklist-Civilian Version (PCL-C).37 A more detailed
description of each of the outcomes is featured in Figure S1.
Design
Consented participants were sequentially randomized at a
1:1 ratio into immediate therapy or delayed therapy groups.
Group assignment was generated by a third party prior to the
start of research, sealed in envelopes labeled by participant
number, and not opened by the researchers until the time of
consent. Participants randomized to the immediate therapy
group began using the BBVR system at week 0 and con-
tinued until week 6, while those randomized to the delayed
therapy group began at week 3 and continued until week 9.
Participants continued all standard-of-care therapies that they
were engaged in pre-consent throughout the duration of their
participation and any changes in treatment were tracked by the
researchers throughout participation.
The BBVR desktop system consisted of a computer and
monitor, wireless headphones, a remote server, and bimanual
game controllers (“pendants”) that measured the position of
the participant’s hands in reference to the controller base
station, which sat between the participant and the computer.
(Figure S2) To ensure safety of the participants, given that
dizziness and decreased balance are commonly associated
with ABI, games were completed from a seated position. Fur-
thermore, the controllers were wired to a base station on the
desk, adjacent to the display. Training while standing would
increase the likelihood of entanglement and interference from
the controller tethers.
All participants started treatment with access to 6 games
(Breakout, Card Island, Kite, Pick & Place, Treasure Hunt,
and Towers), which they played uni-manually (i.e., using only
1 arm) the first week to get accustomed to the system. Games
trained various motor and cognitive deficits associated with
ABI. For example, Card Island tested participants working
memory by presenting them with a set of face-down playing
cards that they had to flip over 2 at a time to try and match
up pictures on the other side. In week 2, participants began
working bi-manually and duration and intensity of treatment
increased incrementally over time. (Figure S3) Further, the
system automatically increased or decreased game difficulty
throughout the session based on performance. After 3 weeks
of active treatment, participants were scheduled concurrently
(i.e., 2 participants at 1 time) to work individually on 2 BBVR
systems that were set-up back to back.38 A summary of the
frequency of assessments is featured in Figure S4.
Statistics
The evaluation of clinical effectiveness of the BBVR system
on the NSI, QIDS-SR, and PCL-C was conducted using a
parallel study design, comparing the 0-to-3-week longitudinal
change in outcomes among the immediate therapy group with
that of the delayed therapy group. The effect estimate was
computed as the difference in the group-level mean longitu-
dinal change from week 0 to week 3 between groups. The
corresponding confidence intervals around the 3-week effect
estimates were estimated using parametric bootstrapping and
false coverage-statement rate adjustment,39 while the p-values
were estimated using 2-sample bootstrapped Kolmogorov-
Smirnov tests (a non-parametric analog of Student’s t-test,
appropriate for comparing distributions of discrete, ordinal
values)40 and limiting the false discovery rate to 5% among
the seven clinical outcomes included in the effectiveness
analysis.41
The evaluation of the clinical effectiveness of the BBVR
system on the ANAM composite score, BBT, JHFT, and
FMA-UE was conducted using a crossover study design
among only those randomized to the delayed therapy group,
comparing the 3-to-9-week longitudinal change in outcomes
with the 0-to-3-week longitudinal change in outcomes. For
each of these outcomes, the effect estimate was computed
as the participant-level difference between the “observed”
(linearly interpolated at week 6 from the 3-to-9-week
longitudinal change) and “expected” (linearly extrapolated
at week 6 from the 0-to-3-week longitudinal change) values.
(Note that the values were interpolated/extrapolated at week 6
so that the effect estimate would be in terms of a 3-week effect,
comparable to the 3-week effect estimates of the NSI, QIDS-
SR, and PCL-C.) The corresponding confidence intervals
around the 3-week effect estimates were computed using
parametric bootstrapping and false coverage-statement rate
adjustment, while the p-values were estimated using 1-sample
Wilcoxon rank-sum tests of the (interpolated/extrapolated)42
within-participant differences in outcome values and limiting
the false discovery rate to 5% among the 7 clinical outcomes
included in the effectiveness analysis.39 Since the JHFT is
relevant only for CVA patients (of whom two CVA patients
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TABLE I. Age, Gender, and Diagnoses by Group
Demographics
Immediate Therapy (n = 11) Delayed Therapy (n = 10) Total (n = 21)
Age (avg years) 42 (SD = 12.01) 39 (SD = 4.93) 41 (SD = 13.38)
Female 18% 40% 29%
CVA 18% 20% 19%
TBI 64% 60% 62%
CVA + TBI 18% 20% 19%
had sufficient data to be included in the analysis), only
2 participants were analyzed, so its corresponding point
estimate and confidence interval should not be considered
robust or reliable.
The evaluation of the dose-response effect of the BBVR
system on the NSI, QIDS-SR, and PCL-C was conducted
using a parallel study design, comparing the 0-to-6-week lon-
gitudinal change in outcomes among the immediate therapy
group with that of the delayed therapy group. For each of these
outcomes, the effect estimate was computed as the difference
in group-level mean longitudinal change from week 0 to
week 6 between the immediate therapy and delayed therapy
groups. The corresponding confidence intervals around the
dose-response effect estimates were computed using paramet-
ric bootstrapping and false coverage-statement rate adjust-
ment, while the p-values were estimated using 2-sample boot-
strapped Kolmogorov-Smirnov tests and limiting the false
discovery rate to 5% among the three dose-response effects.
Note that the difference in group-level means isolates the
6- vs 3-week dose-response effect of the BBVR system by
itself, subtracting out the effects of usual care and natural
convalescence.
The correlations between participant-level BBVR game
performance and longitudinal changes in outcomes (7 clinical
outcomes) were evaluated using a 3-step procedure: first,
the participant-level longitudinal trend in game performance
was estimated for every game within a multilevel/hierarchical
modeling framework using a 3-level generalized linear mixed
model (GLMM) with participant- and game-level random
intercepts and slopes and an identity link function; second,
each participant’s “observed” 3-week change in clinical out-
comes concurrent with the BBVR system was computed,
using linear interpolation for the clinical endpoints that were
not captured every 3 weeks; and third, Spearman’s rank cor-
relation coefficient ρ was used to measure the monotonic
association between participant-level game performance and
longitudinal change in clinical outcomes. The correspond-
ing confidence intervals CIρ were computed analytically per
CIρ = tanh (arctanh (ρ) ± 2∗(n – 3)−1/2), where n is the number
of observations. Spearman’s rank correlation was preferred
over Pearson’s correlation, because the latter assumes linearity
while the former has the more relaxed assumption of mono-
tonicity. Note that the correlation estimates did not account for
the statistical error associated with the estimated longitudinal
trend in game performance, the measurement error of the
interpolated-observed 3-week change in clinical outcomes,
nor the multiplicity effect of multiple hypothesis testing; so,
the confidence intervals CIρ are likely overly liberal – that
is, the confidence intervals around the correlation coefficient
estimates are likely unrealistically tight.42
Finally, we used the clinical effectiveness estimates and
confidence intervals to conduct post-hoc estimates of mini-
mum sufficient sample sizes to achieve 80% power in order
to help inform future randomized controlled trials. This was
conducted by using the mean and standard deviations of the
estimated effects as the corresponding mean and standard
error of a 2-sided t-distributed effect, and then solving for the
sample size sufficient to achieve 80% power.
RESULTS
Demographics and clinical characteristics are reported in
Table I. A majority of participants were male (71%) and
had suffered a TBI (versus a CVA or TBI + CVA; 62%).
The largest portion of participants had experienced a mild
TBI (33%), with 28% of participants diagnosed with a more
severe TBI, 19% having suffered a CVA, and 19% reporting
both a TBI and CVA. The most commonly report cause of
injury was motor vehicle accident (33%). Blast injuries during
deployment accounted for 14% of injuries. The remaining
causes of injury were sports-related (14%), unspecified (19%),
and other (19%; including carotid artery dissection, sudden
cardiac death, fragment wound to the head, and hemorrhage
following a fall). Time since ABI varied greatly, with the
most recent being 6 weeks prior to participation, and the most
distal having occurred over 15 years prior (xx̄ = 66 months).
Participant’s endorsement and electronic medical record
review at baseline indicated that 24% of participants suffered
from current comorbid psychological symptoms, such as
depression and anxiety (including PTSD). Additionally, 38%
of participants expressed persisted neurobehavioral symp-
toms, such as dizziness, poor coordination, light sensitivity,
etc., and 42% of participants experienced regular headaches.
As expected, a majority of participants (67%) endorsed
cognitive deficits at baseline, including slowed processing
speeds, speech difficulties, and post-traumatic amnesia.
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TABLE II. Estimated Clinical Effectiveness and Dose Response of BBVR
Estimated Clinical Effectiveness
Clinical Outcome Design Three-Week Effect (95% CI) p-value
PCL-C Parallel 0.86 (−5.11 to 6.83) 0.802
QIDS-SR Parallel 0.10 (−2.19 to 2.40) 0.317
NSI Parallel 1.24 (−5.99 to 8.48) 0.396
ANAM Cross-over −1.07 (−2.27 to 0.13) 0.074
BBT Cross-over −3.99 (−13.14 to 5.17) 0.461
JHFT Cross-over −31.61 (−65.04 to 1.82) 0.500
FMA-UE Cross-over −0.56 (−4.18 to 3.06) 0.675
PCL-C w/o CVA Parallel 0.07 (−7.26 to 7.4) 0.649
QIDS-SR w/o CVA Parallel 0.84 (−1.8 to 3.48) 0.268
NSI w/o CVA Parallel 3.77 (−4.41 to 11.95) 0.124
ANAM w/o CVA Cross-over −0.56 (−1.52 to 0.4) 0.297
BBT w/o CVA Cross-over −3.36 (−14.83 to 8.11) 0.688
FMA-UE w/o CVA Cross-over 0.36 (−3.48 to 4.19) 1.000
Clinical Outcome Design Six- vs three-Week Effect (95% CI) p-value
PCL-C Parallel 0.83 (−3.28 to 4.93) 0.943
QIDS-SR Parallel 0.11 (−1.47 to 1.7) 0.602
NSI Parallel 1.29 (−3.62 to 6.2) 0.877
Note that the 3-week effect estimates and confidence intervals (CI) were estimated using parametric bootstrapping with false coverage-statement rate
adjustment; p-values were estimated using one-sample Wilcoxon rank-sum tests of the within-patient difference (interpolated) for crossover designs, and
two-sample bootstrapped Kolmogorov-Smirnov tests of the between-group differences for parallel designs, limiting the false discovery rate at 5% among the
seven outcomes.
The dose-response effect estimates and confidence intervals (CI) were estimated using parametric bootstrapping; p-values were estimated using two-sample
bootstrapped Kolmogorov-Smirnov tests of the between-dose differences. Post Traumatic Stress Disorder (PTSD) Checklist-Civilian Version (PCL-C), Quick
Inventory of Depressive Symptomatology-Self-Report (QIDS-SR), Neurobehavioral Symptom Inventory (NSI), Automated Neuropsychological Assessment
Metrics (ANAM), Box and Blocks Test (BBT), Jebsen-Taylor Hand Function Test (JHFT), Fugl-Meyer Assessment of Upper Extremity (FMA-UE).
Participants expressed high system enjoyment and usability
through the Participant Feedback Form and USE Question-
naire at both 3 (xx̄ = 80% and xx̄ = 73% respectively) and
6 weeks (xx̄ = 81% and xx̄ = 79% respectively) of active
treatment with the BBVR system. When reporting positive
aspects of BBVR, participants commonly stated the games
were fun, and that they perceived improvement in memory,
strength, and concentration. A few participants expressed
interest in continuing BBVR treatment upon completion of
the research. Additionally, the provider who ran the treatment
sessions reported that approximately half of the participants
stated that they would like to utilize the system if it were
available for home-based treatment.
Similar reports were demonstrated through the provider
(OT/COTA) Feedback Form and Computer System Usability
Questionnaire at 3 (xx̄ = 83%, xx̄ = 86%) and 6 weeks of active
treatment (xx̄ = 80, xx̄ = 84%). Provider reports stated the
activities were engaging and appropriately challenging for the
participants. In addition, providers indicated that the system
allowed 2 participants to receive therapy simultaneously.
While the overall feedback about the BBVR system was
positive, some patients did report headaches, which they
associated with the brightness of the computer screen. This
was relieved in most cases through the use of tinted glasses,
although 1 patient withdrew from the study because of
headaches. All other study withdrawals were due to non-
research-related circumstances. (Figure S5) In addition,
most participants expressed dissatisfaction with the con-
trollers, saying that the magnetic tracking system was
easily disrupted by the presence of other nearby magnetic
items.43
Regarding clinical effectiveness, adjunct therapy with the
BBVR system was associated with positive (i.e., increase) in
the 3-week effect estimates for NSI (xx̄ = 1.24, 95% CI −5.99
to 8.48, p = 0.396), QIDS-SR (xx̄ = 0.10, 95% CI −2.19 to
2.4, p = 0.317), and PCL-C (xx̄ = 0.86, 95% CI −5.11 to
6.83, p = 0.802), as well as negative (i.e., decrease) 3-week
effect estimates for ANAM (xx̄ = −1.07, 95% CI −2.27 to
0.13, p = 0.074), BBT (xx̄ = −3.99, 95% CI −13.14 to 5.17,
p = 0.461), JHFT (xx̄ = −31.61, 95% CI −65.04 to 1.82, p =
0.500), and FMA-UE (xx̄ = −0.56, 95% CI −4.18 to 3.06, p =
0.675), albeit none of these clinical effects reached statistical
significance at 95% confidence (p > 0.05). These results are
summarized in Table II. To determine if diagnosis played a
role in clinic outcomes, the same analyses were ran excluding
participants who had only experienced a CVA. Similar effects
were found when participants with just CVA were removed
from the analysis, with the notable difference being that, while
ANAM scores still showed a negative 3-week effect estimate
(xx̄ = −0.56, 95% CI −1.52 to 0.40, p = 0.297), the effect was
no longer approaching significance.
The 6- vs 3-week dose-response effect estimates were
positive (i.e., increase) for NSI (xx̄ = 0.83, 95% CI −3.28
to 4.93, p = 0.943), QIDS-SR (xx̄ = 0.11, 95% CI −1.47
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TABLE III. Spearman’s Rank Correlation Estimates (95% Confidence Intervals) Between Participant-Level Average Daily Improvement
in Game Performance and BBVR-Associated 3-Week Longitudinal Change in Clinical Outcomes
Three-Week Clinical Change
Three-week effect on PCL Three-week effect on QIDS Three-week effect on NSI
Towers 0.595 (0.198 to 0.824) 0.043 (−0.415 to 0.484) 0.395 (−0.054 to 0.711)
Breakout 0.284 (−0.19 to 0.651) 0.023 (−0.432 to 0.468) −0.055 (−0.483 to 0.394)
Treasure hunt −0.063 (−0.499 to 0.398) −0.251 (−0.63 to 0.224) 0.107 (−0.349 to 0.522)
Musical drums 0.306 (−0.215 to 0.691) −0.268 (−0.68 to 0.273) 0.027 (−0.468 to 0.509)
Submarine rescue 0.534 (0.079 to 0.805) −0.123 (−0.565 to 0.374) −0.107 (−0.542 to 0.374)
Card island −0.01 (−0.458 to 0.442) −0.117 (−0.539 to 0.351) −0.239 (−0.614 to 0.224)
Arm slalom −0.004 (−0.478 to 0.472) −0.234 (−0.638 to 0.271) 0.279 (−0.211 to 0.656)
Treasure xylophone 0.22 (−0.284 to 0.629) −0.032 (−0.513 to 0.464) 0.212 (−0.292 to 0.624)
Pick and place −0.296 (−0.658 to 0.178) −0.119 (−0.54 to 0.35) −0.186 (−0.578 to 0.276)
Kite −0.163 (−0.571 to 0.31) 0.111 (−0.357 to 0.535) −0.408 (−0.719 to 0.038)
Avalanche −0.007 (−0.481 to 0.469) 0.471 (−0.024 to 0.78) −0.001 (−0.476 to 0.474)
Three-week effect on ANAM Three-week effect on BBT Three-week effect on FM
Towers 0.217 (−0.534 to 0.777) 0.12 (−0.649 to 0.768) −0.131 (−0.739 to 0.595)
Breakout −0.2 (−0.77 to 0.547) 0.615 (−0.176 to 0.923) 0.122 (−0.601 to 0.735)
Treasure hunt −0.133 (−0.74 to 0.593) −0.494 (−0.893 to 0.339) −0.235 (−0.784 to 0.52)
Musical drums 0.733 (0.119 to 0.942) 0.036 (−0.695 to 0.731) 0.531 (−0.221 to 0.887)
Submarine rescue 0.25 (−0.509 to 0.79) 0.06 (−0.683 to 0.742) 0.583 (−0.148 to 0.902)
Card island −0.75 (−0.946 to −0.155) −0.181 (−0.792 to 0.612) −0.026 (−0.687 to 0.659)
Arm slalom 0.183 (−0.559 to 0.762) 0.277 (−0.544 to 0.827) −0.331 (−0.821 to 0.44)
Treasure xylophone 0.5 (−0.261 to 0.878) 0.265 (−0.553 to 0.823) 0.287 (−0.478 to 0.805)
Pick and place 0 (−0.673 to 0.673) −0.374 (−0.858 to 0.464) 0.078 (−0.628 to 0.714)
Kite 0.15 (−0.582 to 0.748) 0.458 (−0.38 to 0.883) −0.131 (−0.739 to 0.595)
Avalanche 0.317 (−0.453 to 0.816) −0.024 (−0.725 to 0.702) −0.461 (−0.866 to 0.307)
Correlations with JHFT could not be computed due to lack of data. Exact p-values could not be computed because of the presence of ties, and so they were
omitted.
to 1.70, p = 0.602), and PCL-C (xx̄ = 1.29, 95% CI –3.62
to 6.20, p = 0.877), yet, again none of these effects were
statistically significant (p > 0.05). Again, similar results were
found when looking only at participant who had experienced
a TBI (including TBI + CVA participants). The results of the
dose-response analyses are summarized in Table II.
Due to insufficient data, correlations between game per-
formance and longitudinal changes in JHFT could not be
computed, so we report the pairwise correlations between the
11 games and remaining 6 clinical outcomes yielded 66 total
correlation estimates. The results of the correlation analyses
were mixed and inconsistent: some correlations were positive
and others were negative, but without any consistent trend
(i.e., correlation coefficient estimates with congruent signs
across BBVR games) for any of the clinical outcomes. Among
the 66 correlations computed, 4 were statistically significant;
however, we choose not to emphasize their confidence inter-
vals here, because they did not account for measurement
error or multiple hypothesis testing, and thus are overly lib-
eral. The results of the correlation analyses are summarized
in Table III.
The post-hoc calculations of minimum sufficient sample
sizes to achieve 80% power for each of the clinical outcomes
are reported in Table IV. These estimates were based
on reported effect size, using a 2-sided 1-sample t-test
where the standard errors (SE) were derived such that
SE = (UL – β)/1.96, where UL is the upper limit of the
corresponding effect size’s 95% confidence interval.44
To achieve 80% power in a parallel-design randomized
controlled trial of the effectiveness of the BBVR system on the
ANAM and JHFT, at least 10 participants should be enrolled
TABLE IV. Results of Post-hoc Calculation of Minimum Sufficient
Sample Sizes to Achieve 80% Power, Based Effect Size Estimates
of Clinical Effectiveness of the BrightBrainer Virtual Rehabilitation
(BBVR) System, Using a Two-Sided, One-Sample t-Test of the
Mean Effect Being Non-zero at 5% Significance
Sample Size Estimate
Outcome Effect Size (β) SE N
NSI 1.24 3.7 144
QIDS-SR 0.1 1.2 2266
PCL-C 0.86 3.1 208
ANAM −1.07 0.62 10
BBT −3.99 4.7 26
JHFT −31.6 17 10
FMA-UE −0.56 1.9 186
The standard errors (SE) were derived from the effect sizes (β) and 95%
confidence intervals in Table IV, such that SE = (UL – β)/1.96, where UL is
the upper limit of the 95% confidence interval. Here, the minimum sufficient
sample size N corresponds to the total sample size for randomization into both
arms of a subsequent randomized clinical trial.
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in total. The careful reader will notice that the minimum
sufficient sample size in each arm for the ANAM (n = 10)
is the same as that which was observed in the current study.
The apparent discordance is the result of limiting the false
discovery rate among the 7 clinical effectiveness analyses,
while each of the post-hoc power analyses were conducted
independently of the others.
DISCUSSION
Overall the provider and patient reports indicated that the sys-
tem demonstrated high levels of technical usability and patient
engagement. Participants expressed enjoyment in using the
system, maintaining such reports from three to six weeks
of treatment, and some noted that they believed the system
would be a good resource for home-based therapy. More-
over, as providers and patients became more familiar with
the technology, this study demonstrated the feasibility for
providers to simultaneously supervise more than 1 patient
at a time, improving clinic efficiency and access to care.
This scheduling was possible when sessions were offset by
15 minutes, allowing for setup prior to the second participant’s
arrival.
While the overall effects on clinical outcomes using the
BBVR system did not reach statistical significance, its use
as an adjunct to traditional therapy showed effectiveness in
improving upper extremity physical function on the JHFT. As
JHFT is a timed test of ADLs, this is indicative of increased
independence in daily life. Performance on other measures
of physical functioning (i.e., BBT and FMA-UE), however
showed some worsening, albeit not statistically significant.
In addition, subjects also seemed to have an increase in
their symptom reporting from pre- to post-BBVR treatment,
just after completion of the 6-week active training period,
as demonstrated by the NSI, QIDS-SR, and PCL-C, which
may be due to increased awareness of their symptoms gained
through participation in this research. While awareness of
ABI-related deficits is generally considered important for
neuropsychological rehabilitation, long-term follow-up would
be required in order to determine if there were any lasting ben-
eficial or detrimental effects post-BBVR treatment.45 Because
this study used each individual as their own control, this
study was not designed to compare the results of subjects
who did or did not use the BBVR system, which has to
be noted when interpreting this data. Similarly, it was noted
that ANAM composite scores actually improved during the
pre-therapy waiting period more than after completion of
the BBVR treatment. While again, this was not statistically
significant, it may have been because of the potential learning
effect with re-administering the ANAM in a shorter period
of time for this group as compared to those completing the
BBVR therapy. These factors should be taken into account
when designing future studies, particularly when using tools
that rely on patient subjective symptom reporting and the
ANAM as outcome measures.
Previous studies using VR as a rehabilitation interven-
tion have shown significant improvements in cognition and
upper extremity function above and beyond that of traditional
therapies.46,47 This pilot study, while not showing statisti-
cally significant improvement in patients using the BBVR
system, does show potential for improvements in clinical
domains. More importantly, it adds to the body of rehabil-
itation literature that VR systems, like the BBVR, can be
used to concurrently treat 2 participants with 1 supervising
provider, which has the potential for increased access to care
and decreased personnel resources needed to treat multiple
patients with ABI. Study results also support previous findings
of high levels of participant enjoyment and perceived clinical
benefits gained from use of virtual rehabilitation.48 This is
important, because a 2011 survey of healthcare providers in
the rehabilitation field noted that patient acceptance is 1 of
the most important factors in determining whether or not
a provider will introduce new technology into treatment.49
Therefore, patient acceptance and enjoyment are important
not only for a participant’s motivation to continue treatment,
but also for providers who are considering implementing novel
technology in their treatment protocol.
Study Limitations
All participants included in this research study were beyond
the sub-acute stage post-injury, with the average time since
injury in this sample being 66 months.14 In general, sub-
acute patients will benefit more from VR than the chronic
population in this study. This is because of brain hyper plas-
ticity coupled with the large intensity of training (and large
number of task-induced repetitions) that VR provides. In
fact, a previous study using VR for individuals with severe
TBI during the acute recovery period, demonstrated signifi-
cant improvements in sustained attention tasks.50 If improve-
ments did occur, the small sample size limits the ability
of this research to determine whether or not BBVR system
had an effect on clinical symptom improvement above and
beyond the control period. Therefore, future research utilizing
the BBVR system would benefit from assessing its compara-
tive effectiveness with other more standard therapies during
the acute/subacute stages of rehabilitation using a larger sam-
ple size.
CONCLUSION
The current study demonstrated the feasibility of implement-
ing the BBVR system into the outpatient rehabilitation of
individuals with ABI in a military Occupational Therapy
setting. Provider and patient reports indicated that the system
demonstrated moderate to high levels of technical usability,
patient engagement, and perceived usefulness. Participants
expressed enjoyment in using the system and endorsement
of improved cognitive and motor function, maintaining such
reports from 3 to 6 weeks of treatment. The post-hoc power
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analyses suggest that clinical effectiveness could be demon-
strated with reasonable sample sizes for all seven outcomes
except QIDS-SR. We believe these data provide sufficient
evidence to justify conducting a follow-up, randomized trial
of the clinical effectiveness of the BBVR system.
SUPPLEMENTARY MATERIAL
Supplementary material is available at Military Medicine online.
FUNDING
This research was supported by an award from the AMEDD Advanced
Medical Technology Initiative (AAMTI) (HU0001-15-2-0012) to the Center
for Rehabilitation Sciences Research, Uniformed Services University of
the Health Sciences, Bethesda, MD; the Henry M. Jackson Foundation for
the Advancement of Military Medicine, Bethesda, MD; and Bright Cloud
International Corp, Edison, NJ. This funding source did not have any role
in the study design, collection, analysis, or interpretation or data, writing of
this manuscript, or decision to submit this article for publication.
Grigore Burdea, PhD is a majority owner of Bright Cloud International,
the company which developed the BrightBrainer Rehabilitation System
Gregory House was previously the Chief Technical Officer of Bright
Cloud International, the company which developed the BrightBrainer Reha-
bilitation System. Dr. House no longer retains that title.
PRESENTATIONS
Posters describing preliminary results of this research were presented at
the Military Health System Research Symposium (MHSRS) from 27–30
August, 2017 Kissimmee, FL; American Congress of Rehabilitation Medicine
(ACRM) from 23–28 October, 2017, Atlanta, GA; DCoE Summit from 19–
21 September, 2017, Silver Spring, MD; 4th Federal Interagency Conference
on Traumatic Brain Injury (FICTBI) from 11–13 June, 2018 Washington,
DC. A conference paper describing gameplay performance during concurrent
(two participants at once) training was presented at the 12th International
Conference on Disability Virtual Reality and Associated Technologies from
4–6 September, 2018 University of Nottingham, England.
SUPPLIERS
aBright Cloud International Corp, c/o Grigore Burdea PhD, 675 US Hwy 1,
CCIT Suite B203, North Brunswick, NJ 08902
REFERENCES
1. Galarneau MR, Woodruff SI, Dye JL, et al: Traumatic brain injury during
operation Iraqi freedom: findings from the United States navy-marine
corps combat trauma registry. J Neurosurg 2008; 108(5): 950–957.
doi:10.3171/JNS/2008/108/5/0950.
2. DoD Worldwide Numbers for TBI. DVBIC.DCoE.mil. http://dvbic.
dcoe.mil/dod-worldwide-numbers-tbi. Published May 21, 2018.
Accessed May 21, 2018.
3. Taub MB, Bartuccio M, Maino D: Visual Diagnosis and Care of the
Patient with Special Needs. Philadelphia, PA, Lippincott Williams
& Wilkins, 2012. https://books.google.com/books?hl=en&lr=&id=e7
vuKBfSCDQC&oi=fnd&pg=PA95&dq=acquired+brain+injury&ots=
tr2pbBOY0n&sig=uEidNk5Nk5Zh7AiEdsJksCj0oY8.
4. Sacco RL, Kasner SE, Broderick JP, et al: An updated defini-
tion of CVA for the 21st century. CVA 2013; 44(7): 2064–2089.
doi:10.1161/STR.0b013e318296aeca.
5. NINDS Cerebral Hypoxia Information Page. https://www.ninds.nih.gov/
Disorders/All-Disorders/Cerebral-Hypoxia-Information-Page
6. Sawnson TM, Isaacson BM, Cyborski CM, et al: Traumatic brain
injury incidence, clinical overview, and policies in the US mili-
tary health system since 2000. Public Health Rep 2017; 132(2):
251–259.
7. Schaechter JD: Motor rehabilitation and brain plasticity
after hemiparetic CVA. Prog Neurobiol 2004; 73: 61–72.
doi:10.1016/j.pneurobio.2004.04.001.
8. Manara JR, Taylor J, Nixon M: Management of shoulder pain after a
cerebrovascular accident or traumatic brain injury. J Shoulder Elbow
Surg 2015; 24(5): 823–829.
9. Lipper-Gruner M, Kuchta J, Hellmich M, Klug N: Neurobehavioural
deficits after severe traumatic brain injury (TBI). Brain Injury. 2006;
20(6): 569–574. doi:10.1080/02699050600664467.
10. Lee YK, Lee CW, Huang MY, Hsu CY, Su YC: Increased risk of
ischemic CVA in patients with mild traumatic brain injury: a nationwide
cohort study. Scand J Trauma Resusc Emerg Med 2014; 22: 66. doi:
10.1186/s13049-014-0066-y.
11. Burke JF, Stulc JL, Skolarus LE, Sears ED, Zahuranec DB, Morgenstern
LB: Traumatic brain injury may be an independent risk factor for CVA.
Neurology 2013; 81(1): 33–39. doi:10.1212/WNL.0b013e318297eecf.
12. Understanding TBI Part 3: The recovery process. msktc.org. http://www.
msktc.org/lib/docs/Factsheets/TBI_Understanding_TBI_part_3.pdf
13. Burdea GC, Defais C, Wong K, et al: Feasibility study of
a new game-based bimanual integrative therapy. ICVR 2013
doi:10.1109/ICVR.2013.6662130.
14. Nudo RJ: Recovery after brain injury: mechanisms and principles. Front.
Hum. Neurosci. 2013; 7: 887. doi:10.3389/fnhum.2013.00887.
15. Kimberley TJ, Samargia S, Moore LG, et al: Comparison of
amounts and types of practice during rehabilitation for traumatic
brain injury and CVA. J Rehabil Res Dev 2010; 47(9): 851–862.
doi:10.1682/JRRD.2010.02.0019.
16. Krakauer JW: Motor learning: its relevance to CVA recovery
and neurorehabilitation. Curr Opin Neurol 2006; 19(1): 84–90.
doi:10.1097/01.wco.0000200544.29915.cc.
17. Gajanan B, Hetali S, Bedekar N, et al: Perspective of neuro
therapeutic approaches preferred for CVA rehabilitation by phys-
iotherapists. Indian J Physiother Occup Ther 2016; 10(1): 47–50.
doi:10.5958/0973-5674.2016.00011.3.
18. de Almeida PM, Santo A, Dias B, et al: Hands-on physiotherapy
interventions and CVA and International Classification of Functionality,
Disability and Health outcomes: a systematic review. Eur J Physiother
2015; 17(3): 100–15. doi:10.3109/21679169.2015.1044466.
19. Pietrzak E, Pullman S, McGuire A: Using virtual reality and videogames
for traumatic brain injury rehabilitation. Games Health J 2014; 3(4):
202–214. doi:10.1089/g4h.2014.0013.
20. Cai L, Chan JS, Yan JH, et al: Brain plasticity and motor prac-
tice in cognitive aging. Front Aging Neurosci 2014; 6(31): 1–12.
doi:10.3389/fnagi.2014.00031.
21. Cox DJ, Davis M, Singh H, et al: Driving rehabilitation for military
personnel recovering from traumatic brain injury using virtual reality
driving simulation: a feasibility study. Mil Med 2010; 175(6): 411–416.
doi:10.7205/MILMED-D-09-00081.
22. Burdea G: Virtual rehabilitation-benefits and challenges. . J Methods
Information Medicine 2003; 42(5): 519–523. PMID: 14654886.
23. Bogdanova Y, Yee MK, Ho VT, et al: Computerized cognitive reha-
bilitation of attention and executive function in acquired brain injury:
a systematic review. J Head Trauma Rehabil 2016; 31(6): 419–433.
doi:10.1097/HTR.0000000000000203.
24. Nakagawa H, Ueno M, Itokazu T, et al: Bilateral movement training
promotes axonal remodeling of the corticospinal tract and recovery of
motor function following traumatic brain injury in mice. Cell Death and
Disease 2013; 4: e534.
25. Steward KC, Cauraugh JH, Summers JJ: Bilateral movement training and
CVA rehabilitation: a systematic review and meta-analysis. J Neurol Sci
2006; 244(1–2): 89–95. doi:10.1016/j.jns.2006.01.005.








ed/article/185/1-2/e203/5527816 by guest on 20 January 2021
26. Burdea G, Polistico K, Krishnamoorthy A, et al: Feasibility study of
the BrightBrainer integrative cognitive rehabilitation system for elderly
with dementia. Disabil Rehabil Assist Technol 2015; 10(5): 421–432.
doi:10.3109/17483107.2014.900575.
27. Han Lee J, Jeonghun K, Wongeun C, et al: A virtual reality system
for the assessment of rehabilitation of the activities of daily living.
Cyberpsychol Behav 2003; 6(4): 383–392.
28. Rabago CA, Wilken JM: Application of a mild traumatic brain injury
rehabilitation program in a virtual reality environment: A case study.
JNPT 2011; 35: 185–193.
29. Lund AM: Measuring usability with the USE Questionnaire. STC
Usability SIG Newsletter 2001; 8: 2.
30. Lewis JR: IBM Computer usability satisfaction questionnaire: psycho-
metric evaluation and instructions for use. Int J Hum-Comput Int 1995;
7(1): 57–78.
31. Fugl-Meyer AR, Jaasko L, Leyman I, et al: The post-CVA hemiplegic
patient population: a method for evaluation of physical performance.
Scand J Rehabil Med 1975; 7(13): 13–31.
32. Mathiowetz V, Volland G, Kashman N, et al: Adult norms for the Box
and Block test of manual dexterity. Am J Occup Ther 1985; 39(6):
386–391. doi:10.5014/ajot.39.6.386.
33. Jebsen RH, Taylor N, Trieschmann RB, et al: An objective and standard-
ized test of hand function. Arch Phys Med Rehabil 1969; 50: 311–319.
34. Ibarra S: Automated neuropsychological assessment metrics. In: Ency-
clopedia of Clinical Neuropsychology. Edited by Kreutzer JS, DeLuca J,
Caplan B. New York, NY, Springer.
35. Cicerone KD: Neurobehavioral Symptoms Inventory. J Head Trauma
Rehabil 1995; 10(3): 1–17.
36. Rush AJ: The 16-item quick inventory of depressive symptomatology
(QIDS) clinician rating (QIDS-C), and self-report (QIDS-SR): A psy-
chometric evaluation in patients with chronic major depression. Biol
Psychiatry 2003; 54(5): 673–583. doi:10.1016/S0006-3223(02)01866-8.
37. Weathers FW, Litz BT, Keane TM, et al The PTSD checklist for DSM-5
(PCL-5) – Standard. [Measurement instrument]. Available from http://
www.ptsd.va.gov/
38. Burdea G, Polistico K, Grampurohit N, et al Concurrent virtual rehabil-
itation of service members post-acquired brain injury – A randomized
clinical study. 12th ICDVRAT; 4–6 September 2018. University of Not-
tingham, England.
39. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practi-
cal and powerful approach to multiple testing. J R Stat Soc Series B Stat
Methodol 1995; 57(1): 289–300.
40. Preastgaard JT: Permutation and bootstrap Kolmogorov-Smirnov tests
for the equality of two distributions. Scand J Stat 1995; 305–322.
41. Benjamini Y, Yekutieli D: False discovery rate–adjusted multiple con-
fidence intervals for selected parameters. JASA 2005; 100(469): 71–81.
doi:10.1198/016214504000001907.
42. Wilcoxon F, Katti S, Wilcox RA: Critical values and probability levels
for the Wilcoxon rank sum test and the Wilcoxon signed rank test. Sel
Tables Mathematical Statistics 1970; 1: 171–259.
43. Sixense Entertainment, (2011), Razer Hydra Master Guide, 11 pp. Avail-
able from: dl.razerzone.com/master-guides/Hydra/HydraOMG-ENG.
pdf. Last accessed March 5, 2018.42. Cohen J. Statistical power analysis
for the behavioral sciences. 2nd ed. 1988.
44. Sawchyn JM, Mateer CA, Suffield JB: Awareness, emotional adjustment,
and injury severity in postacute brain injury. J Head Trauma Rehabil
2005; 4: 301–314.
45. Turolla A, Dam M, Ventura L, et al: Virtual reality for the
rehabilitation of the upper limb motor function after CVA: a
prospective controlled trial. J Neuroeng Rehabil 2013; 10(85): 1–9.
doi:10.1186/1743-0003-10-85.
46. Gamito P, Oliveria J, Coelho C, et al: Cognitive training on CVA patients
via virtual reality-based serious games. Disabil Rehabil 2015; 39(4):
385–388. doi:10.3109/09638288.2014.934925.
47. Thornton M, Marshall S, McComas H, et al: Benefits of activity and vir-
tual reality based balance exercise programmes for adults with traumatic
brain injury: perceptions of participants and their caregivers. Brain Injury
2005; 19(12): 989–1000. doi:10.1080/02699050500109944.
48. Chen CC, Bode RK: Factors influencing therapists’ decision-
making in the acceptance of new technology devices in CVA
rehabilitation. Am J Phys Med Rehabil 2011; 90: 415–425.
doi:10.1097/PHM.0b013e318214f5d8.
49. Dvorkin AY, Ramaiya M, Larson EB, et al: A “virtually minimal”
visuo-haptic training of attention in severe traumatic brain injury. J
NeuroEnging Rehab 2013; 10: 92. http://www.jneuroengrehab.com/
content/10/1/92. 9.
50. Eldridge SM, Chan CL, Campbell MJ, et al: CONSORT 2010 statement:
extension to randomized pilot and feasibility trials. BMJ 2016; 355.








ed/article/185/1-2/e203/5527816 by guest on 20 January 2021
